Answers are grounded in this paper and cite their sources.
Peripheral T-cell lymphomas (PTCLs) represent a group of rare hematological cancers of mature T-cell or natural killer cell origin accounting for 10% to 15% of all lymphomas. 1Although many patients have poor outcomes, some achieve long-term survival. 2,3Thus, identifying prognostic biomarkers is important to facilitate riskadapted therapy.Chromosomal rearrangements are critical in the molecular pathogenesis of nearly all types of hematologic neoplasms. 4The best-characterized rearrangements in PTCLs involve the anaplastic lymphoma kinase (ALK) gene, which result in oncogenic ALK fusion proteins and define a specific World Health Organization (WHO) subtype (ALK-positive anaplastic large cell lymphoma [ALCL], representing 6% to 8% of PTCLs). 2,5,6ALK also serves as a prognostic marker: patients with ALK-positive ALCLs have better outcomes than those with ALK-negative ALCLs or other nodal PTCLs, including angioimmunoblastic T-cell lymphoma (AITL) and PTCL, not otherwise specified (NOS). 2,7The molecular pathogenesis of other PTCLs is being elucidated. 8Recurrent chromosomal rearrangements involving the DUSP22-IRF4 locus on 6p25.3 (DUSP22 rearrangements) and the TP53 homolog TP63 on 3q28 recently were reported in ALK-negative ALCL. 9-12DUSP22 rearrangements are associated with decreased expression of dual-specificity phosphatase-22, an enzyme that regulates mitogen-activated protein kinase signaling. 10,13,14A retrospective study found that DUSP22 rearrangements were associated with favorable outcomes in ALK-negative ALCL. 12TP63 rearrangements encoding p63 fusion proteins were associated with aggressive clinical behavior and poor outcomes. 11,12n the present study, we evaluated the prognostic impact of DUSP22 and TP63 rearrangements in diagnostic tumor biopsy specimens from a population-based Danish cohort of 138 patients with nodal PTCLs.Formalin-fixed, paraffin-embedded tumors from patients diagnosed with PTCL between 1984 and 2011 were retrieved from the pathology departments at 3 Danish tertiary referral centers (Aarhus, Herlev, and Odense University Hospitals).Specimens were pretreatment biopsy specimens from newly diagnosed PTCL patients aged $16 years for whom pre-and posttreatment clinical information was available.Clinicopathological data were obtained from the population-based database of the Danish National Lymphoma Registry, supplemented by medical records.Cases were reviewed and classified by expert hematopathologists, and re-reviewed to assure concordance with current WHO criteria. 15The study was approved by The Central Denmark Region Committees on Health Research Ethics (record 1-10-72-392-12), the Danish Data Protection Agency (record 1-16-02-26-11), and the institutional review boards at the participating institutions
No takes yet. Share an insight, caveat, or question.
Pedersen et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: